FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases

benzinga.com/general/biotech/25/05/45418687/fda-fast-tracks-abbvies-new-lung-cancer-therapy-emrelis-for-tough-lung-cancer-cases

The U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie Inc.’s (NYSE:ABBV) Emrelis (telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE)…

This story appeared on benzinga.com, 2025-05-14 19:25:05.
The Entire Business World on a Single Page. Free to Use →